Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;45(6):805-812.
doi: 10.1097/FTD.0000000000001114. Epub 2023 Jun 15.

Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Escitalopram Pharmacokinetics: A Cohort Study

Georgios Schoretsanitis  1   2   3 , Magnus Strømmen  4   5 , Hege-Merete Krabseth  6 , Arne Helland  4   6 , Olav Spigset  4   6
Affiliations

Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Escitalopram Pharmacokinetics: A Cohort Study

Georgios Schoretsanitis et al. Ther Drug Monit. .

Abstract

Background: Changes in the gastrointestinal physiology after bariatric surgery may affect the pharmacokinetics of medications. Data on the impact of different surgical techniques on the pharmacokinetics of commonly prescribed antidepressants such as escitalopram are limited.

Methods: This case-only prospective study investigated escitalopram-treated patients who underwent bariatric surgery at hospitals in Central Norway. Escitalopram concentrations were assessed using serial blood samples obtained during a dose interval of 24 hours preoperatively and at 1, 6, and 12 months, postoperatively. The primary outcomes were changes in the area under the time-concentration curve (AUC 0-24 ) with secondary outcomes, including full pharmacokinetic profiling. We performed repeated-measures analysis of variance for the AUC 0-24 and secondary outcomes.

Results: Escitalopram-treated obese patients who underwent sleeve gastrectomy (n = 5) and Roux-en-Y gastric bypass (n = 4) were included. Compared with preoperative baseline, dose-adjusted AUC 0-24 values were within ±20% at all time points, postoperatively in the sleeve gastrectomy and oux-en-Y gastric bypass groups, with the largest changes occurring 1 month postoperatively (+14.5 and +17.2%, respectively). No statistically significant changes in any pharmacokinetic variables over time were reported; however, there was a trend toward increased maximum concentrations after surgery ( P = 0.069).

Conclusions: Our findings suggest that bariatric surgery has no systematic effect on the pharmacokinetics of escitalopram. However, because of the substantial interindividual variation, therapeutic drug monitoring can be considered to guide postoperative dose adjustments.

Trial registration: ClinicalTrials.gov NCT03460379.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare. G. Schoretsanitis has served as a consultant for HLS Therapeutics and Thermo Fisher Scientific and has received speaker fees from HLS Therapeutics. The authors have no competing interests to declare.

Figures

FIGURE 1.
FIGURE 1.
Total body weight (A), body mass index (B), body fat (C), AUC0-24 (D), Cmax (E), CL/F (F), t1/2 (G), and Vd/F (H) preoperatively (baseline) and 1, 6, and 12 months after bariatric surgery in 5 patients undergoing sleeve gastrectomy (“sleeve”) and 4 patients undergoing Roux-en-Y gastric bypass (“bypass”). Data are presented as medians with interquartile ranges.
See this image and copyright information in PMC

References

    1. Collaboration NCDRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377–1396. - PMC - PubMed
    1. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77. - PMC - PubMed
    1. Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–136. - PMC - PubMed
    1. Warrings B, Samanski L, Deckert J, et al. Impact of body mass index on serum concentrations of antidepressants and antipsychotics. Ther Drug Monit. 2021;43:286–291. - PubMed
    1. Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine disposition in obesity: potential implications for patient safety. J Clin Psychopharmacol. 2018;38:172–179. - PubMed

Associated data